OncoMatch/Clinical Trials/NCT04157127
Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
Is NCT04157127 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Autologous DC Therapy for pancreatic adenocarcinoma.
Treatment: Autologous DC Therapy — This is a phase 1, first in human, dose escalation study for safety and feasibility of multi-dose dendritic cell (DC) therapy for pancreatic ductal adenocarcinoma (PDAC) including adenosquamous carcinoma administered after surgical resection of PDAC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Disease stage
Excluded: Stage IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: nonstandard neoadjuvant chemotherapy regimen
Use of nonstandard neoadjuvant chemotherapy regimen, as determined by the Investigator
Lab requirements
Blood counts
Hemoglobin ≥ 8.0 gm/dL; Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3; Platelet count ≥ 75,000 /mm3
Kidney function
Liver function
Total bilirubin ≤ 1.5 times upper limit of normal (ULN), AST (SGOT) and ALT (SGPT) ≤ 2.5 times the ULN
Adequate kidney, liver, bone marrow function, and immune function, as follows, within 28 days prior to registration: Hemoglobin ≥ 8.0 gm/dL; ANC ≥ 1,500 cells/mm3; Platelet count ≥ 75,000 /mm3; Total bilirubin ≤ 1.5x ULN; AST (SGOT) and ALT (SGPT) ≤ 2.5x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Baylor College of Medicine Medical Center - McNair Campus · Houston, Texas
- Baylor St. Lukes Medical Center · Houston, Texas
- Dan L. Duncan Cancer Center at Baylor College of Medicine · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify